Top-News
Donnerstag,
28.04.2016 14:35
von
PR Newswire
| Aufrufe: 89
BioElectronics' Drug-free ActiPatch® Pain Therapy
pixabay.com
PR Newswire
FREDERICK, Md., April 28, 2016
FREDERICK, Md., April 28, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, announces that its drug-free ActiPatch® product was noted in the United Kingdom's Express Newspaper Health Section, http://www.express.co.uk/life-style/health/664330/arthritis-pain-pills-warning-sufferers-taking-too-many-drugs-fight-agony. The paper has a circulation of 400,000 that will increase the awareness of ActiPatch therapy for arthritis and chronic pain.
The article entitled "Arthritis pain pills warning: Sufferers taking too many drugs to fight agony" describes the recent Arthritis Research UK/Daily Telegraph survey reveals the severe impact of pain and excessive drug use among the 8.5 million Britons now suffering from arthritis. The Arthritis Research UK survey showed the following:
- Fewer than half (46%) feel satisfied with the current pain treatment they are receiving from their GP or healthcare professional.
- The vast majority (76%) say the pain prevents them from living life to the full.
- A huge number (80%) say their mobility is affected.
- More than three in five (64%) report problems sleeping because of pain.
The article notes ActiPatch's drug-free mechanism of action and its effectiveness in reducing pain, which improves quality life with less dependence on strong painkillers.
ActiPatch is clinically proven treatment for osteoarthritis as demonstrated in an independently conducted double blind, placebo-controlled, randomized clinical trial, which was published in the peer, reviewed journal Rheumatology (www.rheumatology.oxfordjournals.org). There was a reported statistically significant reduction in pain and a significant improvement in the WOMAC² index. In addition, patients in the treatment group reported a statistically significant reduction in NSAID compared to the placebo group.
About BioElectronics Corporation
BioElectronics Corporation is the maker of a leading family of affordable, disposable, drug-free, medical devices. ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. Please visit www.bielcorp.com for clinical evidence and a video http://actipatch.com/why-actipatch/ on how it works.
Contact:
Grace Holdings
732 335 1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-drug-free-actipatch-pain-therapy-300259047.html
SOURCE BioElectronics Corporation
Werbung
Mehr Nachrichten zur Bioelectronics Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
